豁痰通痹汤治疗冠心病PCI术后痰瘀痹阻证患者的临床研究

发布时间：2018-10-21 09:27

【摘要】：目的:观察豁痰通痹汤对冠心病PCI术后痰瘀痹阻证患者血脂水平、心绞痛症状、中医症候积分的影响,评价豁痰通痹汤的临床疗效。方法:根据标准入选冠心病PCI术后痰瘀痹阻证患者共60例,随机分为对照组、治疗组各30例。对照组给予西医常规治疗,治疗组则为西医常规治疗+豁痰通痹汤,疗程均为3个月。观察治疗前后两组患者血脂水平、心绞痛症状以及中医证候积分的变化情况。结果:(1)血脂指标:经治疗,两组病例的血脂水平(TG、TC、HDL-C、LDL-C)均明显改善(治疗组:1.73±0.74,4.38±0.94,1.23±0.31,3.11±0.76vs0.96±0.29,2.86±0.51,1.53±0.44,1.36±0.34;对照组:1.88±0.82,4.67±0.86,1.18±0.31,3.11±0.72vs1.32±0.66,3.40±0.82,1.46±0.53,1.62±0.42),与治疗前相比有极显著统计学差异(P0.01);治疗后,治疗组病例 TC(2.86±0.51vs3.40±0.82)、LDL-C(1.36±0.34vs1.62±0.42)疗效显著优于对照组(P0.01),TG(0.96±0.29vs1.32±0.66)疗效较对照组好(P0.05),而HDL-C(1.53±0.44vs1.62±0.42)疗效较对照组无显著差异。(2)心绞痛疗效:治疗组和对照组均能改善患者心绞痛症状,治疗组的总有效率为90%,对照组的总有效率为83.3%,治疗组稍优于对照组,但无统计学差异(P0.05)。(3)中医症候积分:两组患者在治疗前后中医症候积分(治疗组:25.87±3.17vs9.93± 1.80,对照组:25.57±2.58vs 13.03±2.36)具有极显著统计学差异(P0.01);治疗组积分(9.93±1.80vs13.03±2.36)改善情况优于对照组,具有统计学意义(P0.05);治疗组在改善胸闷不适(1.87±1.04vs 2.53±1.04)和呕恶痰涎(0.87±1.01vs1.60±1.10)的积分方面优于对照组(P0.05)。(4)安全性指标:治疗期间两组患者血常规及肝肾功能检查均未见明显异常改变;两组病例均无肌肉酸痛、过敏等不良反应;两组患者均无致命性出血、支架内血栓等事件发生。结论:在常规西医治疗的基础上加用豁痰通痹汤,可进一步改善冠心病PCI术后患者血脂水平、改善中医症候积分,其有效性及安全性值得肯定。
[Abstract]:Objective: to observe the effect of Huatan Tongbi decoction on blood lipid level, angina pectoris symptom and TCM symptom score in patients with phlegm stasis obstruction syndrome after coronary heart disease (PCI), and to evaluate the clinical curative effect of Huatan Tongbi decoction. Methods: according to the standard, 60 patients with phlegm and stasis obstruction after PCI were randomly divided into control group (n = 30) and treatment group (n = 30). The control group was treated with routine western medicine, the treatment group was treated with traditional western medicine, the course of treatment was 3 months. The changes of blood lipid level, angina pectoris symptom and TCM syndromes were observed before and after treatment. 缁撴灉:(1)琛，

本文编号：2284694